Mephentermine Dependence with Psychosis

1988 ◽  
Vol 152 (1) ◽  
pp. 129-131 ◽  
Author(s):  
Uday G. Joshi ◽  
Shripathy M. Bhat
Keyword(s):  
Pressor Agent ◽  
Chronic Psychosis

Dependence on mephentermine, a widely used sympathomimetic pressor agent, is so far unreported, although misuse of inhalers is recognised. A case of mephentermine dependence associated with chronic psychosis is reported here. Psychosis initially surfaced with chronic dexamphetamine abuse, but was sustained for 3 years by mephentermine. After a period of remission lasting for 4 years, the patient again developed psychosis on restarting abuse of mephentermine, which lasted for 5 years.

Possible antidepressant/mania-inducing effects of methionine: a reappraisal of the effects of methionine in chronic psychosis using modern diagnostic criteria

1989 ◽  
Vol 4 (3) ◽  
pp. 175-181
Author(s):  
J.F. Lipinski ◽  
R.C. Alexander
Keyword(s):  
Monoamine Oxidase ◽  
Diagnostic Criteria ◽  
Monoamine Oxidase Inhibitor ◽  
Manic Episode ◽  
Oxidase Inhibitor ◽  
Descriptive Data ◽  
Antidepressant Effects ◽  
Chronic Psychosis

SummaryThe authors have reviewed 13 published studies on methionine administration, usually in combination with a monoamine oxidase inhibitor (MAOI), to chronically psychotic patients, using modern (DSM-III) diagnostic criteria. Four of these studies contained sufficient descriptive data to allow reappraisal of the effects. The results of the review suggest that a proportion of the patients experienced the induction of a manic episode/antidepressant effects rather than the reported worsening of schizophrenia while treated with a methionine-MAOI combination. It is suggested that these observations are consistent with recent findings that S-adenosyl-L-methionine (SAMe) has antidepressant and mania-inducing effects.

Chronic psychosis related to benzydamine hydrochloride abuse

Neurocase ◽  
2019 ◽  
Vol 25 (3-4) ◽  
pp. 156-158 ◽  
Author(s):  
Meltem Gürü ◽  
Yasir Şafak ◽  
Gül Ferda Cengiz ◽  
Erkan Kuru ◽  
Sibel Örsel
Keyword(s):  
Chronic Psychosis

CHRONIC PSYCHOSIS FOLLOWING EPILEPSY

1958 ◽  
Vol 114 (9) ◽  
pp. 845-845
Author(s):  
IRVING J. FARBER
Keyword(s):  
Chronic Psychosis

Caffeine-Induced Psychosis

CNS Spectrums ◽  
2009 ◽  
Vol 14 (3) ◽  
pp. 127-131 ◽  
Author(s):  
Dawson W. Hedges ◽  
Fu Lye Woon ◽  
Scott P. Hoopes
Keyword(s):  
Antipsychotic Medication ◽  
Healthy People ◽  
Caffeine Intake ◽  
Adenosine Antagonist ◽  
Dopamine Transmission ◽  
Chronic Caffeine ◽  
Chronic Psychosis

ABSTRACTAs a competitive adenosine antagonist, caffeine affects dopamine transmission and has been reported to worsen psychosis in people with schizophrenia and to cause psychosis in otherwise healthy people. We report of case of apparent chronic caffeine-induced psychosis characterized by delusions and paranoia in a 47-year-old man with high caffeine intake. The psychosis resolved within 7 weeks after lowering caffeine intake without use of antipsychotic medication. Clinicians might consider the possibility of caffeinism when evaluating chronic psychosis.

scholarly journals Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis

2021 ◽  
Author(s):  
John R. Kelly ◽  
Priyola Gounden ◽  
Aoibheann McLoughlin ◽  
Zahra Legris ◽  
Therese O’Carroll ◽  
...  
Keyword(s):  
Targeted Interventions ◽  
Metabolic Monitoring ◽  
Chronic Psychosis

A-8 Developmental Cognitive Phenotypes in First-Episode Psychosis and Longitudinal Cognitive Change Following Antipsychotic Treatment

2021 ◽  
Vol 36 (6) ◽  
pp. 1030-1030
Author(s):  
Milena Y Gotra ◽  
Elmma Khalid ◽  
Madison M Dykins ◽  
Scot K Hill
Keyword(s):  
Cognitive Ability ◽  
Antipsychotic Medication ◽  
Cognitive Change ◽  
First Episode Psychosis ◽  
First Episode ◽  
Healthy Controls ◽  
Significant Group ◽  
Cognitive Improvement ◽  
Episode Psychosis ◽  
Chronic Psychosis

Abstract Objective The present study applied a developmentally based subgrouping procedure previously examined in chronic psychosis patients to a sample of first-episode psychosis (FEP) and examined change in cognition following treatment with antipsychotic medication. Method Medication naïve FEP patients (n = 119; age = 27.96; 63.9% male; 62.2% White, 32.8% Black, 5.0% Other) recruited during initial hospitalization were categorized into groups based on 1) estimated premorbid intellectual ability and 2) the discrepancy between predicted (modeled on 151 healthy controls) and current cognitive ability. Consistent with findings from chronic psychosis samples, groups were characterized as Preserved (n = 46; average premorbid, no discrepancy), Deteriorated (n = 44; average premorbid, significant discrepancy), and Compromised (n = 29, low premorbid and current cognitive ability). A mixed analysis of variance was used to examine change in a composite cognitive score derived from a comprehensive neuropsychological battery at baseline, 6 weeks, and 12 months. Results There was a significant group by time interaction [Figure 1; F(5.4142.4) = 2.81, p = 0.02] in which the Preserved group performed similar to healthy controls across all time points, the Compromised group demonstrated stable deficits after treatment, and the Deteriorated group diverged from the Compromised group at 6 weeks and 12 months. Discussion There is considerable cognitive heterogeneity in FEP at baseline and after initiation of antipsychotic medication. Findings of cognitive improvement in the Deteriorated group after treatment initiation suggests a differential response to antipsychotic medications that was not found in the Compromised or Preserved groups. Future work may benefit from examining medication and symptom severity as potential factors contributing to the unique change observed in the Deteriorated group.

scholarly journals Psychosis and recreational use of MDMA (“Ecstasy”)

1993 ◽  
Vol 10 (3) ◽  
pp. 162-163 ◽  
Author(s):  
Eamon Keenan ◽  
Maurice Gervin ◽  
Arthur Dorman ◽  
John J O'Connor
Keyword(s):  
Drug Treatment ◽  
National Drug ◽  
Treatment Centre ◽  
Recreational Use ◽  
Paranoid Psychosis ◽  
Chronic Psychosis

AbstractA seventeen year old man attended the National Drug Treatment Centre with a paranoid psychosis following ingestion of Methylene dioxy methamphetamine (MDMA). He had been taking MDMA on a recreational basis over a five month period. Although chronic psychosis after heavy use of MDMA has been reported there are no pervious reports of psychosis following recreational use. This report highlights the psychological dangers of this drug, which has become widely misused in Dublin over the last two years.

scholarly journals Inflexibility processes as predictors of social functioning in chronic psychosis

Psychosis ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 234-244
Author(s):  
Tatiana Arboleya ◽  
Ana González-Menéndez ◽  
Helena Ordoñez ◽  
David G. Pando ◽  
Mercedes Paino
Keyword(s):  
Social Functioning ◽  
Chronic Psychosis

GREY MATTER DEFICITS IN CHRONIC PSYCHOSIS NOT PRESENT AT FIRST EPISODE

2010 ◽  
Vol 117 (2-3) ◽  
pp. 460-461 ◽  
Author(s):  
Heike C. Schmidt ◽  
John McFarland ◽  
Mohamed Ahmed ◽  
Mark A. Elliott ◽  
Dara M. Cannon ◽  
...  
Keyword(s):  
Grey Matter ◽  
First Episode ◽  
Chronic Psychosis
Sign in / Sign up

Export Citation Format

Share Document